The global burden of chronic kidney disease and the way forward

Ethnicity and Disease

Volumn 15, Issue 3, 2005, Pages 418-423

  Alebiosu, C O ^a,c   Ayodele, O E ^b  

^a OLABISI ONABANJO UNIVERSITY   (Nigeria)

^b LADOKE AKINTOLA UNIVERSITY OF TECHNOLOGY   (Nigeria)

^c Olabisi Onabanjo University Teaching Hospital Sagamu   (Nigeria)

Author keywords

Burden; Chronic kidney disease; Prevention

Indexed keywords

AFRICA; AUSTRALIA; CHINA; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIABETIC NEPHROPATHY; DISEASE COURSE; EPIDEMIOLOGICAL DATA; ETHNIC AND RACIAL GROUPS; EUROPE; GENETIC PREDISPOSITION; GLOMERULONEPHRITIS; HEALTH EDUCATION; HUMAN; HYPERTENSION; INCIDENCE; INDIA; JAPAN; KIDNEY FAILURE; LEAD POISONING; LOW BIRTH WEIGHT; MEDLINE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PAKISTAN; PREVALENCE; RACE DIFFERENCE; REVIEW; RISK FACTOR; SCREENING TEST; SMOKING; SOUTH AMERICA; SOUTHEAST ASIA; UNITED STATES;

CHRONIC DISEASE; DEVELOPING COUNTRIES; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; PREVALENCE; WORLD HEALTH;

EID: 24344469598     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. National Kidney Foundation-K/DOQI. Clinical Practice Guidelines for chronic kidney disease, evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1): S1-S266.
2. Murray CJL. Quantifying the burden of disease - the technical basis for disability adjusted life years. Bull World Health Organ. 1994; 72(3):429-445.
3. Remuzzi G. A research program for COMGAN. ISN News. July 2001:1-6.
4. Feest TG, Mistry CD, Grimes DS, Mallick NP. Incidence of advanced chronic renal failure and the need for end-stage renal replacement treatment. BMJ. 1990;301:897-900.
5. McGeown MG. Prevalence of advanced renal failure in Northern Ireland. BMJ. 1990;301:900-903.
6. Iseki K, Kawazeo N, Osawa A, Fukiyama K. Survival analysis of dialysis patients in Okinawa, Japan. Kidney Int. 1993;43:404-409.
7. Kurokawa K, Nangaku M, Saito A, Inagi R, Miyata T. Current issues and future perspectives of chronic renal failure. J Am Soc Nephrol. 2002;13:S3-S6.
8. Salako BL, Ayodele OE, Kadiri S, Arije A. Prevalence of hepatitis B and C viruses in predialysis patients with chronic renal failure. Afr J Med Med Sci. 2002;31:311-314.
9. Alebiosu CO. Detrimental effects of late referral for dialysis. Afr J Health Sci. 2001;8:78-81.
10. Akinsola W, Odesanmi WO, Ogunniyi JO, Ladipo GOA. Diseases causing chronic renal failure in Nigerians - a prospective study of 100 cases. Afr J Med Med Sci. 1989;18:131-135.
11. US Renal Data System. USRDS 1998. Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1998.
12. Levey AS, Beto Ja, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease; What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis. 1998;32:853-905.
13. Salako BL. Managing chronic renal disease in Nigeria. Niger Med J. 2001;40(3):75-77.
14. Arije A, Kadiri S, Akinkugbe OO. The viability of hemodialysis as a treatment option for renal failure in a developing economy. Afr J Med Med Sci. 2000;29:311-314.
15. Bamgboye EL. Hemodialysis: management problems in developing countries, with Nigeria as a surrogate. Kidney Int. 2003; 63(83):93.
16. Naicker S. End-stage renal disease in sub-Saharan and South Africa. Kidney Int. 2003;63:119.
17. Fogazzi GB, Attolou V, Kadiri SL, Fenili D, Priuli F. A nephrological program in Benin and Togo (West Africa). Kidney Int. 2003;63:56.
18. Barsoum RS. End-stage renal disease in North Africa. Kidney Int. 2003;63:111.
19. Sakhuja V, Sud K. End-stage renal disease in India and Pakistan: burden of disease and management issues. Kidney Int. 2003;63:115.
20. Sitprija V. Nephrology in South East Asia: fact and concept. Kidney Int. 2003;63:128.
21. Shanyan Lin. Nephrology in China: a great mission and momentous challenge. Kidney Int. 2003;63:128.
22. Mcdonald SP, Russ GR. Burden of end-stage renal disease among indigenous peoples in Australia and New Zealand. Kidney Int. 2003; 63:123.
23. Zatz R, Romão JE Jr, Noronha IL. Nephrology in Latin America, with special emphasis on Brazil. Kidney Int. 2003;63:131.
24. Cueto-Manzano AM. Peritoneal dialysis in Meyico. Kidney Int. 2003;63:90.
25. Collins A, Xue JL, Ma JZ, Louis T. Estimating the number of patients and medicare cost for end stage renal disease in the US to the year 2010. J Am Soc Nephrol. 2000;11:133A.
26. Schaubel DE, Morrison HI, Desmeules M, Parsons DA, Fenton SA End-stage renal disease in Canada: Prevalence Projections to 2005. CMAJ. 1999;160:1557-1663.
27. US Renal Data System. 1999 Annual Data Report. Bethesda, Md: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1999.
28. Rychlik I, Miltenberger-Miltenyi G, Ritz E. The drama of the continuous increase in end-stage renal failure patients with type 2 diabetes mellitus. Nephrol Dial Transplant. 1998; 13(suppl 8):6-10.
29. Alebiosu CO, Ayodele O. E. Increasing prevalence of diabetes as a cause of end stage renal disease in Nigeria. Trop Doct. 2004. In press.
30. Obesity and overweight. Available at: www.WHO/obesity/overweight.htm. Accessed on: May 23, 2004.
31. Praga M, Hernandez E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2001;16:1790-1798.
32. Meier-Krische HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70-74.
33. Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in lgA nephritis. Am J Kidney Dis. 2001; 37:720-727.
34. Couser WG. Glomerulonephritis. Lancet. 1999;353:1509-1515.
35. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269-1276.
36. Jha P, Ranson MK, Nguyen SN. Estimates of global and regional smoking prevalence in 1995, by age and sex. Am J Public Health. 2002;92:1002-1006.
37. Chase HP, Garg SK, Marshall G, et al. Cigarette smoking increases the risk of albuminuria among subjects with type 1 diabetes. JAMA. 1991;265:614-617.
38. Orth SR, Ogata H, Ritz E. Smoking and the kidney. Nephrol Dial Transplant. 2000;15:1509-1511.
39. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 1994;17:126-131.
40. Whelton PK. The evolving epidemic of cardiovascular and renal diseases: a worldwide challenge. Curr Opin Nephrol Hypertens. 1995;4:215-217.
41. Alebiosu CO. An update on progression promoters in chronic renal diseases. Natl Med Assoc. 2003;95:30-42.
42. Coresh J, Wei GL, McQuillin G, et al. Prevalence of high blood pressure and elevated serum creatinine levels in the US: findings from the third National Health and Nutrition Examination Survey (1998-1994). Arch Intern Med. 2001;161:1207-1216.
43. Chobanian AV, Bakris GL, Black HR, et al, and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure - The JNC 7 Report. JAMA. 2003;289:2560-2571.
44. Salako BL, Ayodele OE, Kadiri S, Arije A. Assessment of blood pressure control in a Black African population. Trop Cardiol. 2002; 28:3-6.
45. Ayodele OE, Alebiosu CO, Salako BL. Differential control of systolic and diastolic blood pressure in Nigerians with essential hypertension. J Natl Med Assoc. 2004;96:310-314.
46. Familoni OB, Alebiosu CO, Odusan O. Factors influencing target organ damage among hypertensive patients in Nigeria. Trop Cardiol. 2003;29(114):21-24.
47. Cuspidi C, Lonati L, Sampieri L, et al. Blood pressure control in a hyptension hospital clinic. J Hypertens. 1999;17:835-841.
48. McClellan WM, Knight DF, Harp H, Brown WM. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. Am J Kidney Dis. 1997;29:368-375.
49. Alebiosu CO. Awareness of kidney diseases in Ogun State University Teaching hospital and environment. Afr J Health Sci. 2003;9:152-155.
50. Hoy WE, Wang Z, Baker PRA, Kelly AM. Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. Kidney Int. 2003;63:66.
51. Ramirez SPB, I-Hong Hsu S, McClellan W. Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program. Kidney Int. 2003;63:61.
52. Brown WW, Collins A, Shu-Cheng Chen, et al. Identification of persons at high risk for kidney disease via targeted screening: The NKF Kidney Early Evaluation Program. Kidney Int. 2003;63:50.
53. Kadiri S, Arije A, Salako BL. Traditional herbal preparations and acute renal failure in South West Nigeria. Trop Doct. 1999;29:241-246.
54. Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis. 1998;31:398-417.
55. Innes A, Rowe PA, Burden RPL, Morgan AG. Early deaths on renal replacement therapy: the need for early nephrological referral. Nephrol Dial Transplant. 1992;7:467-471.
56. Avorn J, Bohn RL, Levy E, et al. Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med. 2002; 162:2002-2006.